Clinical Trials
81 trialsCOSMIC
ASH Research Collaborative
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Institutes of Health Clinical Center (CC)
REMAKE
The Royal Wolverhampton Hospitals NHS Trust
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
MMExFFPE
BIWAKO
A Study of Ninlaro in Real World Clinical Practice in China
Takeda
AI
Zhongnan Hospital
NIRVANA
Columbia University
LIBERATE
University Health Network, Toronto
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
LOOMIS
Oxford University Hospitals NHS Trust
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
Tel-Aviv Sourasky Medical Center
MYRACLE
Nantes University Hospital
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
PeriPharm
Longitudinal Data Registry of Plasma Cell Dyscrasia
Shanghai Zhongshan Hospital
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
UNC Lineberger Comprehensive Cancer Center
Survivorship
University of Modena and Reggio Emilia
Mobile Health Device Study for Myeloma Patients
Memorial Sloan Kettering Cancer Center
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
ASH Research Collaborative Data Hub
ASH Research Collaborative
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer
HemaTMA
Tampere University Hospital
FATIGUE
University of Aberdeen
genetics MM
Siriraj Hospital
Bergamo Lymphoid Cancer Registry
A.O. Ospedale Papa Giovanni XXIII
Registry PCD
Siriraj Hospital
ORHEO
Hospira, now a wholly owned subsidiary of Pfizer
ENROL
Hospital Universitari Vall d'Hebron Research Institute
CoMMpass
Multiple Myeloma Research Foundation
The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures
Centre Hospitalier Universitaire de Nice
GAGNE
University Hospital, Bordeaux
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyricâ„¢ Flow Cytometer
Becton, Dickinson and Company
CHIME
The Christie NHS Foundation Trust
Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Centre Hospitalier Universitaire de Saint Etienne
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
National Institutes of Health Clinical Center (CC)
Changing Over Time of Ascorbic Acid After Chemotherapy
Maastricht University Medical Center
iTIMM
Institute of Cancer Research, United Kingdom
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
OHSU Knight Cancer Institute
SPACE2
Weprom
DECIMA
Guy's and St Thomas' NHS Foundation Trust
THERMAL
Malaghan Institute of Medical Research
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
MYMO
Centre Hospitalier Universitaire de Nīmes
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
National Institutes of Health Clinical Center (CC)
ICARE
European Georges Pompidou Hospital